Panelists discuss how the logistical challenge of the new test requiring separate appointments (tracer injection followed by imaging 5 days later) is offset by scheduling flexibility because of the tracer’s 78-hour half-life and the technology essentially providing a “virtual biopsy” without invasive procedures.
A panelist discusses how genomic classifiers play a crucial role in determining whether treatment intensification with agents like abiraterone is beneficial for patients with high-risk localized prostate cancer.
Panelists discuss how molecular imaging could transform metastatic kidney cancer management by helping determine whether cytoreductive nephrectomy is necessary and assessing treatment response to guide therapy escalation or de-escalation.
A panelist discusses how a 62-year-old man with high-risk localized prostate cancer was treated with intensified therapy, including abiraterone plus radiation, but experienced tolerability issues with the traditional fasting formulation.
Laura E. Davis, MD, discusses the link between early onset prostate cancer and persistent poverty.
One prominent theory suggests that younger generations of graduating urologists face increased financial pressures due to higher student loan debt.
The ARASTEP trial is exploring the combination of darolutamide plus ADT vs ADT alone in patients with high-risk biochemical recurrence of prostate cancer.
The system is now cleared for use in prostates up to 150 cm3.
Panelists discuss the expanding clinical development of cretostimogene across multiple NMIBC populations and treatment strategies, highlighting ongoing trials exploring its use as monotherapy and in combination with agents like gemcitabine or pembrolizumab, with the goal of optimizing efficacy, safety, and bladder preservation across diverse risk groups.
Panelists discuss the final BOND-3 trial results, highlighting intravesical cretostimogene’s strong efficacy, durable responses, and excellent safety profile in BCG-unresponsive carcinoma in situ (CIS), reinforcing its potential as a well-tolerated, bladder-preserving treatment option in a population with limited therapeutic choices.
Amy E. Krambeck, MD, discusses how to define success and how to determine the optimal timing for adding on a new partner.
Olivares cautioned that HIFU is not suitable for all patients, particularly those with more aggressive disease, for whom complete gland removal may still be necessary.
“The takeaway is that on a population level, on a health care system perspective, it's more cost-effective and safer to do transperineal prostate biopsy,” says Mitchell M. Huang, MD.
David Stanley, MD, FACS, discusses current trends and unmet needs in the treatment of patients with kidney stones.
Alicia K. Morgans, MD, MPH, highlights quality of life data from the phase 3 ARANOTE trial.
The findings strongly support a proactive approach to identifying and referring patients with poor urinary function after RP.
Treatment with the Revi System led to durable QOL benefits at 24 months, even among those patients who did not achieve the primary end point.
Panelists discuss how molecular imaging might help with complex renal mass decision-making, potentially identifying aggressive clear cell biology that would warrant radical rather than partial nephrectomy, though anatomical details would still require conventional imaging.
A panelist discusses how patient comorbidities like diabetes and liver disease influence abiraterone formulation selection, noting that some physicians worry about steroid effects on blood glucose and the importance of monitoring liver function.
A panelist discusses how food significantly affects abiraterone absorption, particularly fatty meals, which can increase absorption to dangerous levels, making the microformulation advantageous by eliminating fasting concerns.
Panelists discuss how the new PET technology could identify lymph node involvement not visible on conventional imaging, providing actionable information for surgical planning or indicating the need for systemic therapy rather than surgery alone.
Anne Schuckman, MD, on optimal sequencing strategies, the SWOG 1602 trial, and the emerging role of ctDNA.
Amir S. Patel, MD, discusses interim findings from a randomized controlled trial of onabotulinumtoxinA injection at the time of HoLEP vs standard treatment.
Panelists discuss the promising results of the BOND-3 trial evaluating intravesical cretostimogene for BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC), highlighting its high complete response rates, favorable safety profile, and potential to offer an effective, bladder-sparing alternative without the toxicity of systemic immunotherapy.
Panelists discuss emerging immunotherapy strategies for BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC), particularly the combination of BCG with systemic checkpoint inhibitors, noting promising response rates but significant toxicity concerns that currently limit widespread adoption to select high-risk patients, pending further trial data and safety protocol development.
The investigators found a clear, dose-response relationship between patient-reported incontinence severity and the subsequent use of incontinence interventions such as artificial sphincters or bulking agents.
Margaret A. Knoedler, MD, discusses the advantages of using the MONARCH platform for mini-PCNL.
Khurshid R. Ghani, MBChB, MS, FRCS, discusses how results from the SOUL trial may shape clinical decision-making regarding stent placement.
“Our findings support that that we do not drop the label of cancer from grade group 1 nomenclature," says Jim C. Hu, MD, MPH.
A significant challenge lies in differentiating prostate cancer symptoms from common age-related issues.
